CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

risperidone

Last Updated: March 1, 2021
Result type: Reports
Project Number: SR0671-000
Product Line: Reimbursement Review

Generic Name: risperidone

Brand Name: Perseris

Manufacturer: HLS Therapeutics Inc.

Therapeutic Area: Schizophrenia, adults

Indications: ​Treatment of schizophrenia in adults.

Manufacturer Requested Reimbursement Criteria1: Treatment of schizophrenia in adults.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule C

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 24, 2020
Call for patient/clinician input closedFebruary 22, 2021
Clarification:

- Patient input submission received from Institute for Advancements in Mental Health

Submission receivedJanuary 29, 2021
Submission acceptedFebruary 12, 2021
Review initiatedFebruary 23, 2021
Draft CADTH review report(s) provided to sponsor for commentMay 07, 2021
Deadline for sponsors commentsMay 18, 2021
CADTH responses on draft review report(s) provided to sponsorJuly 09, 2021
Expert committee meeting (initial)July 21, 2021
Draft recommendation issued to sponsorAugust 03, 2021
To
August 05, 2021